Nothing Special   »   [go: up one dir, main page]

FR2775187B1 - Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo - Google Patents

Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo

Info

Publication number
FR2775187B1
FR2775187B1 FR9901903A FR9901903A FR2775187B1 FR 2775187 B1 FR2775187 B1 FR 2775187B1 FR 9901903 A FR9901903 A FR 9901903A FR 9901903 A FR9901903 A FR 9901903A FR 2775187 B1 FR2775187 B1 FR 2775187B1
Authority
FR
France
Prior art keywords
epothilone
antiproliferative
manufacture
composition
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9901903A
Other languages
English (en)
Other versions
FR2775187A1 (fr
Inventor
Terence O'reilly
Markus Wartmann
Manuel Litchman
Pamela Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Priority claimed from US09/233,993 external-priority patent/US6302838B1/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR2775187A1 publication Critical patent/FR2775187A1/fr
Application granted granted Critical
Publication of FR2775187B1 publication Critical patent/FR2775187B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FR9901903A 1998-02-25 1999-02-16 Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo Expired - Fee Related FR2775187B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones

Publications (2)

Publication Number Publication Date
FR2775187A1 FR2775187A1 (fr) 1999-08-27
FR2775187B1 true FR2775187B1 (fr) 2003-02-21

Family

ID=27517450

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9901903A Expired - Fee Related FR2775187B1 (fr) 1998-02-25 1999-02-16 Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo

Country Status (10)

Country Link
US (4) US6635666B2 (fr)
EP (1) EP1056453B1 (fr)
JP (1) JP2002504511A (fr)
AU (1) AU755944B2 (fr)
BE (1) BE1011980A5 (fr)
CA (1) CA2319752A1 (fr)
FR (1) FR2775187B1 (fr)
IT (1) ITMI990375A1 (fr)
NZ (1) NZ506187A (fr)
WO (1) WO1999043320A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT873341E (pt) 1995-11-17 2004-02-27 Biotechnolog Forschung Mbh Gbf Derivados de epotilona preparacao e utilizacao
DK0941227T5 (da) 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
EP0977563B1 (fr) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, intermediaires utilises dans leur synthese, analogues et utilisations de celles-ci
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
AU768220B2 (en) 1998-11-20 2003-12-04 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
CA2366697A1 (fr) * 1999-02-26 2000-08-31 Larry Helson Regime de traitement pour les cancers hormonodependants
AU3606600A (en) * 1999-02-26 2000-09-14 Napro Biotherapeutics, Inc. Treatment regimen for prostate cancer
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US6414015B1 (en) 2000-01-28 2002-07-02 Utah State University Laulimalide microtubule stabilizing agents
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
BR0206511A (pt) 2001-01-25 2003-10-21 Bristol Myeres Squibb Company Formulação parenteral para análogos de epotilona
CN100341505C (zh) * 2001-01-25 2007-10-10 布里斯托尔-迈尔斯斯奎布公司 用于治疗癌症的埃博霉素类似物的给药方法
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
MXPA03006412A (es) * 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
WO2002066038A1 (fr) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Traitement de tumeurs refractaires a l'aide de derives d'epothilone
RU2003128312A (ru) 2001-02-20 2005-02-10 Бристол-Маерс Сквибб Компани (Us) Производные эпотилона, используемые для лечения резистентных опухлей
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
CA2449077A1 (fr) 2001-06-01 2002-12-12 Gregory D. Vite Derives d'epothilone
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
NZ533940A (en) * 2002-01-14 2007-06-29 Novartis Ag Combinations comprising epothilones and anti-metabolites
EP1340498A1 (fr) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Utilisation d'épothilones dans le traitement de maladies du cerveau associées aux processus de prolifération
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
DE10217254A1 (de) * 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (fr) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combinaison d'analogues d'epothilone et agents chimiotherapeutiques utiles dans le traitement des maladies proliferatives
ES2336937T3 (es) * 2002-08-23 2010-04-19 Sloan-Kettering Institute For Cancer Research Sintesis de epotilonas, sus intermedios, analogos y usos.
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2280014B1 (fr) 2002-09-23 2013-10-23 Bristol-Myers Squibb Company Procèdes de préparation, d'isolation et de purification d'épothilone B
EP1553939A1 (fr) * 2002-10-11 2005-07-20 Dana-Farber Cancer Institute, Inc. Derives epothilone pour le traitement du myelome multiple
BR0317150A (pt) * 2002-12-09 2005-11-01 Novartis Ag Estabilizadores de microtúbulos em stents para o tratamento de estenose
US20040146632A1 (en) * 2003-01-23 2004-07-29 Cristina Sayman Effective multi-component penetrating and flavoring marinade
US20060205795A1 (en) * 2003-06-27 2006-09-14 David Parkinson Cancer treatment with epothilones
JP2007504259A (ja) * 2003-09-02 2007-03-01 ノバルティス アクチエンゲゼルシャフト エポチロンでの癌処置
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
EP1640004A1 (fr) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Utilisation des epothilones pour le traitement des metastases osseuses ou du cancer des os
EP1824458A1 (fr) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Bille enrobee de keratine comprenant de l'epothilone ou un analogue d'epothilone, ainsi que preparation et administration de cette bille
EP1817013B1 (fr) * 2004-11-18 2008-06-04 Brystol-Myers Squibb Company Bille a enrobage enterique comprenant de l'ixabepilone
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
KR20090005310A (ko) * 2006-04-05 2009-01-13 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
AU2007319193A1 (en) * 2006-11-15 2008-05-22 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
US20100173718A1 (en) 2007-06-20 2010-07-08 Saluc Technologies S.A. Convertible dining / billiard table
EP2065054A1 (fr) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinaisons comprenant une prostaglandine et leurs utilisations
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanoparticules à surface modifiée
CN102256615A (zh) 2009-01-14 2011-11-23 爱勒让治疗公司 拟肽大环化合物
EP2210584A1 (fr) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Composition polymère stable comprenant un copolymère séquencé d'épothilone et amphiphile
CA2898996A1 (fr) * 2013-01-23 2014-07-31 The University Of Toledo Agents anticancereux hautement selectifs ciblant le cancer de poumon non a petites cellules et d'autres formes de cancer
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127432A (en) * 1872-06-04 Improvement in tuckers for sewing-machines
US142990A (en) * 1873-09-23 Improvement in machines for burnishing the shanks of boots and shoes
US260098A (en) * 1882-06-27 Rolls for longitudinally slitting railroad-rails
US87634A (en) * 1869-03-09 Improvement in grain-storehouses
US203876A (en) * 1878-05-21 Improvement in piston water-meters
US34452A (en) * 1862-02-18 Improvement in railroad joints or chairs
US253697A (en) * 1882-02-14 John halley and alexandee baee
US203938A (en) * 1878-05-21 Improvement in wire fences
US220295A (en) * 1879-10-07 Improvement in hinges
US176429A (en) * 1876-04-25 Improvement in nut-locks
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2167201A1 (fr) * 1993-07-15 1995-01-26 Kristin M. Lundy Derives amides de macrolides antibiotiques a cycle de 16 chainons
PT873341E (pt) * 1995-11-17 2004-02-27 Biotechnolog Forschung Mbh Gbf Derivados de epotilona preparacao e utilizacao
EP0923583A1 (fr) 1996-08-30 1999-06-23 Novartis AG Procede de fabrication d'epothilones, et composes intermediaires obtenus au cours de ce procede
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DK0941227T5 (da) 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP0977563B1 (fr) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, intermediaires utilises dans leur synthese, analogues et utilisations de celles-ci
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (fr) * 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Metathese olefinique selective de substrats bifonctionnels ou polyfonctionnels dans du dioxyde de carbone comprime en tant que milieu de reaction
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ATE368036T1 (de) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
KR100669174B1 (ko) * 1998-02-05 2007-01-17 노파르티스 아게 유기화합물 함유 조성물
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2322157C (fr) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, de leurs intermediaires et de leurs analogues
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
NZ508326A (en) 1998-06-18 2003-10-31 Novartis Ag A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
US6121029A (en) * 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
WO1999067253A2 (fr) 1998-06-22 1999-12-29 Novartis Ag Desmethylepothilones
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
DE19848306A1 (de) * 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
AU768220B2 (en) 1998-11-20 2003-12-04 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
AU2001295195B2 (en) 2000-04-28 2007-02-01 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
WO2005085209A1 (fr) * 2004-03-10 2005-09-15 Kureha Corporation Composé aminé basique et son usage

Also Published As

Publication number Publication date
FR2775187A1 (fr) 1999-08-27
AU2927999A (en) 1999-09-15
US20060223867A1 (en) 2006-10-05
US20020028839A1 (en) 2002-03-07
US7091226B2 (en) 2006-08-15
CA2319752A1 (fr) 1999-09-02
JP2002504511A (ja) 2002-02-12
NZ506187A (en) 2003-11-28
US6635666B2 (en) 2003-10-21
US20040024033A1 (en) 2004-02-05
AU755944B2 (en) 2003-01-02
BE1011980A5 (fr) 2000-03-07
ITMI990375A1 (it) 1999-08-25
EP1056453B1 (fr) 2010-10-06
US7875601B2 (en) 2011-01-25
WO1999043320A1 (fr) 1999-09-02
US20050165071A1 (en) 2005-07-28
EP1056453A1 (fr) 2000-12-06

Similar Documents

Publication Publication Date Title
FR2775187B1 (fr) Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
FR2733684B1 (fr) Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
FR2780281B1 (fr) Compositions comprenant des nanopigments d'oxydes de fer pour la coloration artificielle de la peau et utilisations
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
DE69918233D1 (de) Polymilchsäure zusammensetzung und daraus hergestellter film
FR2765801B1 (fr) Utilisation de monoesters d'arbutine comme agent depigmentant
BRPI9810519B1 (pt) derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
MA26641A1 (fr) Utilisation de conjuges pef-ifn- & en association avec la ribavirine pour la fabrication de medicaments
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
FR2708201B1 (fr) Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
FR2781148B1 (fr) Composition cosmetique comprenant des pigments et un agent antitranspirant, utilisation d'une telle composition
FR2728783B1 (fr) Prothese d'articulation metatarso-phalangienne totale du premier rayon du pied
EE200900049A (et) Etinl”stradiooli ja drospirenooni sisaldav farmatseutiline kompositsioon kasutamiseks rasestumisvastase vahendina
FR2714603B1 (fr) Composition dermatologique et son utilisation pour la préparation d'un médicament.
MD283F1 (ro) Compozitie de ingrediente pentru balsamul tonifiant "legenda"
FR2780427B1 (fr) Poutre mixte bois-beton pour la construction et l'ouvrage d'art
FR2643643B1 (fr) Compositions utilisables pour la preparation de membranes d'etancheite et membranes obtenues
FR2818907B1 (fr) Utilisation de la brivudine pour la preparation d'une composition pharmaceutique
FR2750046B1 (fr) Compositions sous forme d'un gel aqueux comprenant un ceramide ou un compose de type ceramide
FR2762526B1 (fr) Malaxeur d'alginate ameliore
FR2746012B1 (fr) Utilisation de la tiamuline pour la preparation d'un medicament comme agent de reversion de la multichimioresistance cancereuse
FR2792833B1 (fr) Utilisation de l'acide n-anisoyl-gamma-aminobutyrique ou de l'acide p-anisique pour la preparation d'une composition pharmaceutique
FR2722688B1 (fr) Utilisation d'un extrait de la plante commiphoramukul comme agent pigmentant ou de culture de melanometique ou pharmaceutique, ou pour la culture des cytes; ou pour la fabrication d'une compostion cosmelanocytes
FR2722991B1 (fr) Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20141031